[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”zielgruppe” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”||30px||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.27.5″ _module_preset=”default” title_text_color=”#10344C” title_font_size=”45px” custom_margin=”||15px|||” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n
Die MIRACLE-Studie vergleicht zwei Behandlungsans\u00e4tze f\u00fcr Patient:innen, die in den letzten 12 Monaten neu mit mittelschwerer bis schwerer Colitis ulcerosa diagnostiziert wurden:<\/p>\n
Patient:innen mit einer Diagnose von mittelschwerer bis schwerer Colitis ulcerosa in den letzten 12 Monaten, die auf die Erstbehandlung (Mesalazin und Prednisolon) nicht ausreichend angesprochen haben.<\/p>\n
Insgesamt 52 Wochen:<\/p>\n
Mirikizumab-Gruppe: 12 Gaben (zun\u00e4chst intraven\u00f6s, dann als Spritze zu Hause)
Azathioprin-Gruppe: T\u00e4gliche Tabletteneinnahme mit Kortison
Ein Wechsel zu Mirikizumab ist nach 24 Wochen m\u00f6glich, falls die Erkrankung weiterhin aktiv ist<\/p>\n
Universit\u00e4tsklinikum Schleswig-Holstein
ClinicalTrials.gov ID: NCT07235904<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” width=”100%” custom_padding=”50px|50px|50px|50px|true|true” border_radii=”on|35px|35px|35px|35px” box_shadow_style=”preset1″ box_shadow_color=”rgba(170,201,207,0.34)” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” header_text_align=”center” header_2_text_align=”center” custom_margin=”||||false|false” text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_code _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”]